SCHEMBL3015989

SCHEMBL3015989

COc1ccc(Cl)cc1S(=O)(=O)N1CCN(c2nc(-c3c(C)cc(C)cc3C)cs2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
RAB9A P51151 2/20 0.53
KDM4E B2RXH2 1/20 0.53
POLB P06746 1/20 0.53
HPGD P15428 1/20 0.53
MAPT P10636 6/20 0.52
LMNA P02545 3/20 0.52
TSHR P16473 2/20 0.52
CYP3A4 P08684 2/20 0.48
CYP2C19 P33261 2/20 0.48
KMT2A Q03164 2/20 0.47
USP2 O75604 2/20 0.47
GAA P10253 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TP53 P04637 1/20 0.47
MAPK1 P28482 2/20 0.46
MEN1 O00255 1/20 0.46
CYP2C9 P11712 1/20 0.46
HTT P42858 1/20 0.45
RECQL P46063 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018867 0.93 ALDH1A1 (0.53) ALDH1A1RAB9AKDM4EPOLBHPGD
SCHEMBL3001254 0.90 ALDH1A1 (0.54) ALDH1A1RAB9AKDM4EPOLBHPGD
SCHEMBL3014565 0.90 ALDH1A1 (0.57) ALDH1A1RAB9AKDM4EPOLBMAPT
SCHEMBL3018738 0.89 ALDH1A1 (0.46) ALDH1A1MAPTLMNATSHRKMT2A
SCHEMBL3016505 0.89 GAA (0.53) ALDH1A1RAB9AMAPTTSHRKMT2A
SCHEMBL3010848 0.88 ALDH1A1 (0.54) ALDH1A1RAB9AKDM4EPOLBHPGD
SCHEMBL3007942 0.88 ALDH1A1 (0.56) ALDH1A1RAB9AKDM4EPOLBHPGD
SCHEMBL3009661 0.88 AR (0.45) ALDH1A1RAB9AMAPTLMNATSHR
SCHEMBL3016587 0.87 AR (0.53) ALDH1A1RAB9AKDM4EPOLBHPGD
SCHEMBL3652353 0.87 MAPT (0.47) ALDH1A1RAB9AKDM4EPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885RAB9A 2943/4885KDM4E 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.